Adherex Activates Phase III Trial With Sodium Thiosulfate In Collaboration With Children's Oncology Group - Quick Facts

(RTTNews) - Adherex Technologies Inc. (ADH, AHX.TO) a biopharmaceutical company, announced activation of a Phase III trial with sodium thiosulfate to prevent hearing loss in children receiving cisplatin-based chemotherapy in collaboration with the Children's Oncology Group.

The goal of this Phase III study is to evaluate in a multi-centered, randomized trial whether sodium thiosulfate or STS is an effective and safe means of preventing hearing loss in children receiving cisplatin chemotherapy for newly diagnosed germ cell, liver, brain , nerve tissue or bone cancers. Eligible children will be 1 to 18 years of age who are scheduled to receive cisplatin according to their disease-specific regimen and, upon enrollment onto this study, will be randomized to receive STS or placebo.

Efficacy of STS will be determined through comparison of hearing sensitivity at follow-up relative to baseline measurements using standard audiometric techniques. The trial is expected to enroll up to 120 patients over approximately three years in up to 230 COG centers in the United States, Canada, Australia and Europe.

For comments and feedback: contact editorial@rttnews.com Copyright(c) 2008 RealTimeTraders.com, Inc. All Rights Reserved

More News:   Market Updates | Stock Alerts | All Trading News | Stock Index